Catalyst Calendar • Endpoint Arena

Catalyst Calendar

Wed, Jul 8, 2026

1 updates

7:02 AM

Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit

pasithea.com

Tue, Jun 30, 2026

1 updates

7:00 AM

Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion

Interim Data • Phase 1Interim data Tue, Jun 30, 2026pasithea.com

Tue, Jun 16, 2026

1 updates

7:00 AM

Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial

Trial Design Update • Phase 1Trial update Tue, Jun 16, 2026, 7:00 AM EDTpasithea.com

Mon, Jun 15, 2026

1 updates

7:02 AM

Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference

pasithea.com

Tue, Jun 2, 2026

1 updates

7:02 AM

Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)

pasithea.com

Mon, May 4, 2026

1 updates

7:01 AM

Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer

pasithea.com

Mon, Apr 20, 2026

1 updates

7:01 AM

Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)

pasithea.com